ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

The idea of self-amplifying gene editing is to get cells to pass on packages of CRISPR machinery to their neighbours, boosting the effect ...

A scientific breakthrough not only promises faster testing for antimicrobial resistance, but also an ethical solution to the ...

CRISPR Therapeutics (NASDAQ:CRSP) is a gene editing company that develops gene-based medicines for serious human diseases ...

Researchers have developed a new biomimetic nanocomposite (mPDA-Cas9) for treating triple-negative breast cancer (TNBC) by combining CRISPR/Cas9 gene ...

OGM was selected as a genome-wide, unbiased method to detect large genomic rearrangements and structural variants (SVs) with sensitivity to variant allele fractions (VAFs) as low as 5% to analyze ...

Venkatesan Sundaresan, a distinguished professor of plant biology and plant sciences at UC Davis, has been awarded a Gates Foundation grant to develop self-cloning crops for Indian farmers.The ...

Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced ...

Scientists have achieved a genetic feat once thought impossible: removing an entire extra human chromosome using gene-editing technology. In a landmar.

Following a clinical hold last October of Intellia Therapeutics Inc.’s Magnitude and Magnitude-2 phase III trials of CRISPR/Cas9 gene editing therapy nexiguran ziclumeran (nex-z) to treat ...

A U.S. clinical-stage genome editing company headquartered in Cambridge, Massachusetts. The company runs global clinical development through external trial sites, with in-house capabilities spanning ...

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...